{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:20:18Z","timestamp":1794896418476,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:00:00Z","timestamp":1794873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:00:00Z","timestamp":1794873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institute","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes (T2D), but their rapid uptake has outpaced understanding of their effects in individuals with eating disorders (EDs). GLP-1 RAs produce sustained effects on appetite, satiety, food reward, and energy intake, raising the possibility of markedly different consequences across ED presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Preliminary studies suggest potential benefit for binge-eating symptoms, consistent with emerging evidence of overlap between binge eating and reward- and impulse-related pathways. Conversely, appetite suppression and attenuation of compensatory responses to negative energy balance could facilitate or mask restriction in individuals vulnerable to anorexia nervosa (AN) or atypical anorexia nervosa (AAN). Empirical evidence remains sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We review neurobiological and genetic evidence relevant to these potentially divergent effects, summarize the clinical literature, and highlight implications for screening and monitoring. Determining who may benefit, who may be harmed, and how to identify risk before treatment should be priorities for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11920-026-01726-9","type":"journal-article","created":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:04:38Z","timestamp":1794891878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Miracle and\/or Minefield? GLP-1 RA Drugs and Eating Disorders"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5069-1776","authenticated-orcid":false,"given":"Rachel","family":"Presskreischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9384-7988","authenticated-orcid":false,"given":"Laura M.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-3264","authenticated-orcid":false,"given":"Cynthia M.","family":"Bulik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,11,17]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.obmed.2025.100640","volume":"57","author":"R Abdelrahman","year":"2025","unstructured":"Abdelrahman R, Sharif S, Musa T, Musa H, Arbab I, Suleiman M. Global trends and focuses of GLP-1 RA in obesity: A bibliometric analysis and visualization from 2014 to 2024. Obes Med. 2025;57:100640.","journal-title":"Obes Med"},{"issue":"1","key":"1726_CR2","doi-asserted-by":"publisher","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","volume":"8","author":"P Berning","year":"2025","unstructured":"Berning P, Adhikari R, Schroer A, Jelwan Y, Razavi A, Blaha M. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open. 2025;8(1):e2457232.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1726_CR3","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1097\/MS9.0000000000002592","volume":"86","author":"A Mahapatro","year":"2024","unstructured":"Mahapatro A, Bozorgi A, Obulareddy S, Jain S, Reddy Korsapati R, Kumar A. Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023. Ann Med Surg. 2024;86(11):6602\u201318.","journal-title":"Ann Med Surg"},{"key":"1726_CR4","doi-asserted-by":"publisher","first-page":"1857078","DOI":"10.3389\/fpsyt.2026.1857078","volume":"17","author":"M Roca Mora","year":"2026","unstructured":"Roca Mora M, Sanchez-Monge M, Balardini Ayoub D, Aguiar-Barros A, Serrano-Porras S, De Filippis R. GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks. Front Psychiatry. 2026;17:1857078.","journal-title":"Front Psychiatry"},{"issue":"8","key":"1726_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.cmet.2026.07.006","volume":"38","author":"M Gonzalez-Rellan","year":"2026","unstructured":"Gonzalez-Rellan M, Drucker D. Weight-loss-independent actions of GLP-1 medicines. Cell Metab. 2026;38(8):1535\u20139.","journal-title":"Cell Metab"},{"issue":"25","key":"1726_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.15585\/mmwr.mm7025e1","volume":"70","author":"J Diesel","year":"2021","unstructured":"Diesel J, Sterrett N, Dasgupta S, Kriss JL, Barry V, Vanden Esschert K, et al. COVID-19 Vaccination Coverage Among Adults - United States, December 14, 2020-May 22, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(25):922\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"1726_CR7","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1001\/archinte.160.22.3401","volume":"160","author":"LR Harrold","year":"2000","unstructured":"Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med. 2000;160(22):3401\u20135.","journal-title":"Arch Intern Med"},{"issue":"16","key":"1726_CR8","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/jama.1990.03440160047035","volume":"263","author":"DK Wysowski","year":"1990","unstructured":"Wysowski DK, Kennedy DL, Gross TP. Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988. JAMA. 1990;263(16):2185\u20138.","journal-title":"JAMA"},{"issue":"17","key":"1726_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJMp2600300","volume":"394","author":"A Banks","year":"2026","unstructured":"Banks A. GLP-1 receptor agonists and eating disorders \u2014 Cause for concern. N Engl J Med. 2026;394(17):1665\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"1726_CR10","doi-asserted-by":"publisher","first-page":"e0005516","DOI":"10.1371\/journal.pgph.0005516","volume":"5","author":"S Jensen","year":"2025","unstructured":"Jensen S, Gualano B, Andreassen P, Scagliusi F, SturtzSreetharan C, Brewis A. Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss. PLOS Glob Public Health. 2025;5(12):e0005516.","journal-title":"PLOS Glob Public Health"},{"key":"1726_CR11","unstructured":"Noguchi Y. GLP-1 obesity drugs can complicate life for people with disordered eating; 2026. Available from: https:\/\/www.npr.org\/2026\/02\/04\/nx-s1-5677633\/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia"},{"key":"1726_CR12","unstructured":"Penn Medicine. The implications of GLP-1 medications for eating disorders care; 2025. Available from: https:\/\/www.pennmedicine.org\/physicians-hub\/physician-article\/implications-of-glp-1-medications-for-eating-disorder-care"},{"issue":"5","key":"1726_CR13","doi-asserted-by":"publisher","first-page":"e13709","DOI":"10.1111\/obr.13709","volume":"25","author":"J Richards","year":"2024","unstructured":"Richards J, Khalsa S. Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. Obes Rev. 2024;25(5):e13709.","journal-title":"Obes Rev"},{"key":"1726_CR14","unstructured":"Szabo L, Kopf M, Syal A. Weight loss drugs like Wegovy may trigger eating disorders in some patients, doctors warn 2024 Available from: https:\/\/www.nbcnews.com\/health\/mental-health\/eating-disorders-increase-weight-loss-drugs-wegovy-zepbound-rcna162124"},{"issue":"2","key":"1726_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"K Allison","year":"2023","unstructured":"Allison K, Chao A, Bruzas M, McCuen-Wurst C, Jones E, McAllister C. A pilot randomized controlled trial of liraglutide 3.0\u00a0mg for binge eating disorder. Obes Sci Pract. 2023;9(2):127\u201336.","journal-title":"Obes Sci Pract"},{"issue":"4","key":"1726_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","volume":"14","author":"A Da Porto","year":"2020","unstructured":"Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):289\u201392.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"4","key":"1726_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/13651501.2025.2549307","volume":"29","author":"A Guerdjikova","year":"2025","unstructured":"Guerdjikova A, Blom T, Mori N, Romo-Nava F, McElroy S. Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial \u2013 a post hoc analysis. Int J Psychiatry Clin Pract. 2025;29(4):280\u20133.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1726_CR18","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards J, Bang N, Ratliff E, Paszkowiak M, Khorgami Z, Khalsa S. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obes Pillars. 2023;7:100080.","journal-title":"Obes Pillars"},{"issue":"4","key":"1726_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"D Drucker","year":"2018","unstructured":"Drucker D. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"2","key":"1726_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1172\/JCI112855","volume":"79","author":"S Mojsov","year":"1987","unstructured":"Mojsov S, Weir G, Habener J. Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616\u20139.","journal-title":"J Clin Invest"},{"issue":"8571","key":"1726_CR21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei M, Bloom S. Glucagon-like peptide-1 7\u201336: a physiological incretin in man. Lancet. 1987;2(8571):1300\u20134.","journal-title":"Lancet"},{"issue":"8","key":"1726_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"M Nauck","year":"1993","unstructured":"Nauck M, Kleine N, \u00d8rskov C, Holst J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741\u20134.","journal-title":"Diabetologia"},{"issue":"5","key":"1726_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40265-017-0706-4","volume":"77","author":"B Geloneze","year":"2017","unstructured":"Geloneze B, de Lima-Junior JC, Velloso LA. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the brain-adipocyte axis. Drugs. 2017;77(5):493\u2013503.","journal-title":"Drugs"},{"key":"1726_CR24","doi-asserted-by":"publisher","first-page":"101352","DOI":"10.1016\/j.molmet.2021.101352","volume":"54","author":"Y Dong","year":"2021","unstructured":"Dong Y, Carty J, Goldstein N, He Z, Hwang E, Chau D, et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021;54:101352.","journal-title":"Mol Metab"},{"key":"1726_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molmet.2019.07.008","volume":"28","author":"Z He","year":"2019","unstructured":"He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY\/AgRP neurons - Implications for energy balance and glucose control. Mol Metab. 2019;28:120\u201334.","journal-title":"Mol Metab"},{"issue":"4","key":"1726_CR26","doi-asserted-by":"publisher","first-page":"e194740","DOI":"10.1172\/JCI194740","volume":"136","author":"R Jalleh","year":"2026","unstructured":"Jalleh R, Talley N, Horowitz M, Nauck M. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026;136(4):e194740.","journal-title":"J Clin Invest"},{"issue":"9","key":"1726_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1726_CR28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","volume":"105","author":"H Kadouh","year":"2020","unstructured":"Kadouh H, Chedid V, Halawi H, Burton D, Clark M, Khemani D. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105(5):1552\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1726_CR29","doi-asserted-by":"publisher","first-page":"e3699","DOI":"10.1002\/dmrr.3699","volume":"39","author":"M Smits","year":"2023","unstructured":"Smits M, Holst J. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how? Diabetes Metab Res Rev. 2023;39(8):e3699.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"1726_CR30","doi-asserted-by":"publisher","first-page":"101403","DOI":"10.1016\/j.ajcnut.2026.101403","volume":"124","author":"J Tronieri","year":"2026","unstructured":"Tronieri J, Allison K, DeRouen K, Amaro A, Collins K, Roy A. Short- and long-term effects of semaglutide 2.4\u00a0mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.","journal-title":"Am J Clin Nutr"},{"issue":"6657","key":"1726_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1126\/science.adj9953","volume":"381","author":"C Bulik","year":"2023","unstructured":"Bulik C, Hardaway J. Turning the tide on obesity? Science. 2023;381(6657):463.","journal-title":"Science"},{"issue":"4","key":"1726_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"C Hendershot","year":"2025","unstructured":"Hendershot C, Bremmer M, Paladino M, Kostantinis G, Gilmore T, Sullivan N. Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. 2025;82(4):395\u2013405.","journal-title":"JAMA Psychiatry"},{"issue":"19","key":"1726_CR33","doi-asserted-by":"publisher","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"M Klausen","year":"2022","unstructured":"Klausen M, Jensen M, M\u00f8ller M, Le Dous N, Jensen A, Zeeman V. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863.","journal-title":"JCI Insight"},{"issue":"22","key":"1726_CR34","doi-asserted-by":"publisher","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","volume":"8","author":"L Probst","year":"2023","unstructured":"Probst L, Monnerat S, Vogt D, Lengsfeld S, Burkard T, Meienberg A. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8(22):e170419.","journal-title":"JCI Insight"},{"issue":"1","key":"1726_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","volume":"10","author":"D Vall\u00f6f","year":"2020","unstructured":"Vall\u00f6f D, Kalafateli A, Jerlhag E. Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Transl Psychiatry. 2020;10(1):238.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"1726_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/medsci13030136","volume":"13","author":"G Amorim Moreira Alves","year":"2025","unstructured":"Amorim Moreira Alves G, Teranishi M, Teixeira de Castro Gon\u00e7alves Ortega A, James F. Perera Molligoda Arachchige A. Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights. Med Sci. 2025;13(3):136.","journal-title":"Med Sci"},{"issue":"5","key":"1726_CR37","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/cercor\/bhaa369","volume":"31","author":"A Haynos","year":"2021","unstructured":"Haynos A, Camchong J, Pearson C, Lavender J, Mueller B, Peterson C. Resting state hypoconnectivity of reward networks in binge eating disorder. Cereb Cortex. 2021;31(5):2494\u2013504.","journal-title":"Cereb Cortex"},{"key":"1726_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neubiorev.2016.01.013","volume":"63","author":"R Kessler","year":"2016","unstructured":"Kessler R, Hutson P, Herman B, Potenza M. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev. 2016;63:223\u201338.","journal-title":"Neurosci Biobehav Rev"},{"issue":"11","key":"1726_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/eat.23776","volume":"55","author":"N Leenaerts","year":"2022","unstructured":"Leenaerts N, Jongen D, Ceccarini J, Van Oudenhove L, Vrieze E. The neurobiological reward system and binge eating: A critical systematic review of neuroimaging studies. Int J Eat Disord. 2022;55(11):1421\u201358.","journal-title":"Int J Eat Disord"},{"issue":"9","key":"1726_CR40","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s44220-026-00698-2","volume":"4","author":"JD Termorshuizen","year":"2026","unstructured":"Termorshuizen JD, Davies HL, Lee SH, Dennis JK, H\u00fcbel C, Johnson JS, et al. Genomic meta-analyses of binge-eating behavior and anorexia nervosa yield insights into the unique and shared biology of eating disorder phenotypes. Nat Ment Health. 2026;4(9):1361\u201377.","journal-title":"Nat Ment Health"},{"key":"1726_CR41","doi-asserted-by":"publisher","first-page":"115940","DOI":"10.1016\/j.bbr.2025.115940","volume":"499","author":"M Lutter","year":"2026","unstructured":"Lutter M. Rare coding mutations in the glucagon-like peptide-2 pathway are associated with increased risk of binge eating disorders. Behav Brain Res. 2026;499:115940.","journal-title":"Behav Brain Res"},{"issue":"3","key":"1726_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","volume":"9","author":"S Robert","year":"2015","unstructured":"Robert S, Rohana A, Shah S, Chinna K, Wan Mohamud W, Kamaruddin N. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study. Obes Res Clin Pract. 2015;9(3):301\u20134.","journal-title":"Obes Res Clin Pract"},{"key":"1726_CR43","doi-asserted-by":"crossref","unstructured":"Keys A, Bro\u017eek J, Henschel A, Mickelsen O, Taylor H. The biology of human starvation. University of Minnesota Press; 1950.","DOI":"10.5749\/j.ctv9b2tqv"},{"issue":"3","key":"1726_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/eat.70002","volume":"59","author":"E Lai","year":"2026","unstructured":"Lai E, Lai B, Wong C, Wong L, Cheng K, Cheng P. Systematic review and meta-analysis of mortality in patients with anorexia nervosa. Int J Eat Disord. 2026;59(3):424\u201349.","journal-title":"Int J Eat Disord"},{"issue":"12","key":"1726_CR45","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3390\/jcm10122555","volume":"10","author":"L Puckett","year":"2021","unstructured":"Puckett L, Grayeb D, Khatri V, Cass K, Mehler P. A comprehensive review of complications and new findings associated with anorexia nervosa. J Clin Med. 2021;10(12):2555.","journal-title":"J Clin Med"},{"issue":"2","key":"1726_CR46","doi-asserted-by":"publisher","first-page":"e2024070304","DOI":"10.1542\/peds.2024-070304","volume":"156","author":"S Trapani","year":"2025","unstructured":"Trapani S, Rubino C. Medical complications of anorexia nervosa. Pediatrics. 2025;156(2):e2024070304.","journal-title":"Pediatrics"},{"issue":"2","key":"1726_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1176\/appi.ajp.2007.07060951","volume":"165","author":"K Eddy","year":"2008","unstructured":"Eddy K, Dorer D, Franko D, Tahilani K, Thompson-Brenner H, Herzog D. Diagnostic crossover in anorexia nervosa and bulimia nervosa: implications for DSM-V. Am J Psychiatry. 2008;165(2):245\u201350.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1726_CR48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1017\/S0033291718001472","volume":"49","author":"K Schaumberg","year":"2019","unstructured":"Schaumberg K, Jangmo A, Thornton L, Birgeg\u00e5rd A, Almqvist C, Norring C. Patterns of diagnostic transition in eating disorders: a longitudinal population study in Sweden. Psychol Med. 2019;49(5):819\u201327.","journal-title":"Psychol Med"},{"issue":"4","key":"1726_CR49","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1176\/appi.ajp.162.4.732","volume":"162","author":"F Tozzi","year":"2005","unstructured":"Tozzi F, Thornton L, Klump K, Fichter M, Halmi K, Kaplan A. Symptom fluctuation in eating disorders: correlates of diagnostic crossover. Am J Psychiatry. 2005;162(4):732\u201340.","journal-title":"Am J Psychiatry"},{"key":"1726_CR50","doi-asserted-by":"crossref","unstructured":"Martin A, Stern C, Carpati MS, Berg R, Ascarrunz D, Quigley L et al. Eating disorder diagnostic crossover: a meta-analysis. Int J Eat Disord. 2026. [Online ahead of print].","DOI":"10.1002\/eat.70175"},{"issue":"1","key":"1726_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40519-026-01831-x","volume":"31","author":"S Elm","year":"2026","unstructured":"Elm S, Petersson S, Carlsson M, Brudin L, Marteinsdottir I, Wanby P. GLP-1 is associated with perfectionism in Swedish women with anorexia nervosa, independent of BMI. Eat Weight Disord EWD. 2026;31(1):25.","journal-title":"Eat Weight Disord EWD"},{"issue":"4","key":"1726_CR52","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajcn\/85.4.967","volume":"85","author":"N Germain","year":"2007","unstructured":"Germain N, Galusca B, Le Roux C, Bossu C, Ghatei M, Lang F. Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. Am J Clin Nutr. 2007;85(4):967\u201371.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1726_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-2002-20519","volume":"34","author":"P Tomasik","year":"2002","unstructured":"Tomasik P, Sztefko K, Malek A. GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res. 2002;34(2):77\u201380.","journal-title":"Horm Metab Res"},{"issue":"12","key":"1726_CR54","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1515\/JPEM.2004.17.12.1623","volume":"17","author":"P Tomasik","year":"2004","unstructured":"Tomasik P, Sztefko K, Starzyk J. Cholecystokinin, glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity. J Pediatr Endocrinol Metab. 2004;17(12):1623\u201331.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"1726_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.psychres.2008.06.040","volume":"169","author":"F Brambilla","year":"2009","unstructured":"Brambilla F, Monteleone P, Maj M. Glucagon-like peptide-1 secretion in bulimia nervosa. Psychiatry Res. 2009;169(1):82\u20135.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1726_CR56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/eat.22264","volume":"48","author":"A Dossat","year":"2015","unstructured":"Dossat A, Bodell L, Williams D, Eckel L, Keel P. Preliminary examination of glucagon-like peptide\u20101 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2015;48(2):199\u2013205.","journal-title":"Int J Eat Disord"},{"issue":"4","key":"1726_CR57","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3945\/ajcn.111.014837","volume":"94","author":"S Naess\u00e9n","year":"2011","unstructured":"Naess\u00e9n S, Carlstr\u00f6m K, Holst J, Hellstr\u00f6m P, Hirschberg A. Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. Am J Clin Nutr. 2011;94(4):967\u201372.","journal-title":"Am J Clin Nutr"},{"key":"1726_CR58","first-page":"489","volume":"66","author":"N Do Ros\u00e1rio Caldas","year":"2022","unstructured":"Do Ros\u00e1rio Caldas N, Braulio V, Brasil M, Furtado V, Carvalho D, Cotrik E. Binge eating disorder, frequency of depression, and systemic inflammatory state in individuals with obesity \u2013 A cross sectional study. Arch Endocrinol Metab. 2022;66:489\u201397.","journal-title":"Arch Endocrinol Metab"},{"issue":"5","key":"1726_CR59","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.physbeh.2008.04.013","volume":"94","author":"A Geliebter","year":"2008","unstructured":"Geliebter A, Hashim S, Gluck M. Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED). Physiol Behav. 2008;94(5):696\u20139.","journal-title":"Physiol Behav"},{"issue":"9","key":"1726_CR60","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/imj.16499","volume":"54","author":"JY Gong","year":"2024","unstructured":"Gong JY, Wentworth JM. Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes. Intern Med J. 2024;54(9):1586\u20137.","journal-title":"Intern Med J"},{"issue":"4","key":"1726_CR61","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ejendo\/lvae024","volume":"190","author":"B Gatta-Cherifi","year":"2024","unstructured":"Gatta-Cherifi B, Mohammedi K, Cariou T, Poitou C, Touraine P, Raverot G. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol. 2024;190(4):257\u201365.","journal-title":"Eur J Endocrinol"},{"key":"1726_CR62","doi-asserted-by":"publisher","first-page":"1638681","DOI":"10.3389\/fcdhc.2025.1638681","volume":"6","author":"Y Koide","year":"2025","unstructured":"Koide Y, Kato T, Hayashi M, Daido H, Maruyama T, Ishihara T. Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study. Front Clin Diabetes Healthc. 2025;6:1638681.","journal-title":"Front Clin Diabetes Healthc"},{"issue":"6","key":"1726_CR63","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/dom.15028","volume":"25","author":"P Behary","year":"2023","unstructured":"Behary P, Alessmii H, Miras A, Tharakan G, Alexiadou K, Aldhwayan M. Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes\/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo\u2010controlled study. Diabetes Obes Metab. 2023;25(6):1731\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1726_CR64","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41366-023-01370-w","volume":"47","author":"G Coppin","year":"2023","unstructured":"Coppin G, Mu\u00f1oz Tord D, Pool E, Locatelli L, Achaibou A, Erdemli A. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. Int J Obes. 2023;47(12):1224\u201331.","journal-title":"Int J Obes"},{"key":"1726_CR65","doi-asserted-by":"publisher","first-page":"105667","DOI":"10.1016\/j.psyneuen.2022.105667","volume":"137","author":"C Van Ruiten","year":"2022","unstructured":"Van Ruiten C, Ten Kulve J, Van Bloemendaal L, Nieuwdorp M, Veltman D, IJzerman R. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022;137:105667.","journal-title":"Psychoneuroendocrinology"},{"key":"1726_CR66","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.obpill.2025.100220","volume":"16","author":"I Goetz","year":"2025","unstructured":"Goetz I, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025;16:100220.","journal-title":"Obes Pillars"},{"issue":"9","key":"1726_CR67","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1007\/s12325-026-03660-x","volume":"43","author":"A Kiyosue","year":"2026","unstructured":"Kiyosue A, Sato M, Cai Z, Fukushima Y, Takai M, Takahashi T. Experience with tirzepatide and weight management during and after a clinical trial in Japanese patients with obesity disease: a qualitative study. Adv Ther. 2026;43(9):4218\u201331.","journal-title":"Adv Ther"},{"issue":"9","key":"1726_CR68","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","volume":"31","author":"C Martin","year":"2025","unstructured":"Martin C, Carmichael O, Carnell S, Considine R, Kareken D, Dydak U. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025;31(9):3141\u201350.","journal-title":"Nat Med"},{"issue":"3","key":"1726_CR69","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/JCP.0000000000001975","volume":"45","author":"A Guerdjikova","year":"2025","unstructured":"Guerdjikova A, Dlugosz H, Wolterman R, McElroy S. Relapse in anorexia nervosa associated with tirzepatide: A case report. J Clin Psychopharmacol. 2025;45(3):287\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1726_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"A Guerdjikova","year":"2024","unstructured":"Guerdjikova A, Ward A, Ontiveros M, McElroy S. Semaglutide misuse in atypical anorexia nervosa\u2014a case report. J Clin Psychopharmacol. 2024;44(2):179\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1726_CR71","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1192\/bjo.2025.10909","volume":"12","author":"L Liekens","year":"2026","unstructured":"Liekens L, Ka\u00efret K, Elst E. Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report. BJPsych Open. 2026;12(1):e2.","journal-title":"BJPsych Open"},{"key":"1726_CR72","doi-asserted-by":"crossref","unstructured":"Saito C, Saito M, Nakagawa M, Iijima T, Tomaru T, Jojima T. Atypical anorexia nervosa developed in a patient with severe obesity and type 2 diabetes following sleeve gastrectomy and postoperative treatment with semaglutide and tirzepatide. Intern Med. 2026:7502\u201326.","DOI":"10.2169\/internalmedicine.7502-26"},{"key":"1726_CR73","doi-asserted-by":"crossref","unstructured":"Budini B, Luo S, Tam M, Stead I, Lee A, Akrami A. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. 2026;93.","DOI":"10.1016\/j.eclinm.2026.103796"},{"issue":"1","key":"1726_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"L Aronne","year":"2024","unstructured":"Aronne L, Sattar N, Horn D, Bays H, Wharton S, Lin W. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"14","key":"1726_CR75","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway F, Jensen C. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"9","key":"1726_CR76","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/oby.24331","volume":"33","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan H, Butsch W, Schulte R, Casacchia N, Le P, Boyer C. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025;33(9):1657\u201367.","journal-title":"Obesity"},{"issue":"1","key":"1726_CR77","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"P Rodriguez","year":"2025","unstructured":"Rodriguez P, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349.","journal-title":"JAMA Netw Open"},{"key":"1726_CR78","doi-asserted-by":"publisher","first-page":"100658","DOI":"10.1016\/j.obmed.2025.100658","volume":"58","author":"M Abdel-Bary","year":"2025","unstructured":"Abdel-Bary M, Brody A, Schmitt J, Prieto K, Wetzel A, Juo Y. Real-world weight change pattern after glucagon-like peptide-1 receptor agonist discontinuation: A 1-year observational study. Obes Med. 2025;58:100658.","journal-title":"Obes Med"},{"key":"1726_CR79","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/eat.70103","volume":"59","author":"JA Siegel","year":"2026","unstructured":"Siegel JA, Mumford EA, Kresovich A, Emery S, Jones C. Eating disorder screen results and GLP-1 awareness, interest, and use in a nationally representative sample of adults in U.S. households. Int J Eat Disord. 2026;59:2217\u201325.","journal-title":"Int J Eat Disord"},{"key":"1726_CR80","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/wps.70096","volume":"25","author":"A Keshen","year":"2026","unstructured":"Keshen A, Allison K, Amaro A, Bulik C, White A, Wnuk S. Consensus-based and research recommendations for GLP-1 RA treatment in the context of eating disorders: A modified Delphi study. World Psychiatry. 2026;25:465\u201374.","journal-title":"World Psychiatry"},{"issue":"3","key":"1726_CR81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/eat.22074","volume":"46","author":"E Concei\u00e7\u00e3o","year":"2013","unstructured":"Concei\u00e7\u00e3o E, Orcutt M, Mitchell J, Engel S, LaHaise K, Jorgensen M. Eating disorders after bariatric surgery: A case series. Int J Eat Disord. 2013;46(3):274\u20139.","journal-title":"Int J Eat Disord"},{"issue":"6","key":"1726_CR82","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s11695-020-04424-4","volume":"30","author":"C Watson","year":"2020","unstructured":"Watson C, Riazi A, Ratcliffe D. Exploring the experiences of women who develop restrictive eating behaviours after bariatric surgery. Obes Surg. 2020;30(6):2131\u20139.","journal-title":"Obes Surg"},{"key":"1726_CR83","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/eat.70180","volume":"59","author":"K Herb Neff","year":"2026","unstructured":"Herb Neff K, Dunford A, Goldschmidt A, Allison K, Richeson A. Eating disorder risk and screening in patients using GLP-1 RAs: Lessons learned from metabolic and bariatric surgery. Int J Eat Disord. 2026;59:2370\u20134.","journal-title":"Int J Eat Disord"},{"issue":"5","key":"1726_CR84","doi-asserted-by":"publisher","first-page":"e0152744","DOI":"10.1371\/journal.pone.0152744","volume":"11","author":"N Gideon","year":"2016","unstructured":"Gideon N, Hawkes N, Mond J, Saunders R, Tchanturia K, Serpell L. Development and psychometric validation of the EDE-QS, a 12 Item Short Form of the Eating Disorder Examination Questionnaire (EDE-Q). PLoS ONE. 2016;11(5):e0152744.","journal-title":"PLoS ONE"},{"issue":"1","key":"1726_CR85","doi-asserted-by":"publisher","first-page":"2441220","DOI":"10.1080\/20523211.2024.2441220","volume":"18","author":"M DiStefano","year":"2025","unstructured":"DiStefano M, Dardouri M, Moore G, Saseen J, Nair K. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025;18(1):2441220.","journal-title":"J Pharm Policy Pract"},{"key":"1726_CR86","unstructured":"Montero A, Sparks G, Presiado M, Hamel L. KFF health tracking poll May 2024: the public\u2019s use and views of GLP-1 drugs; 2024. Available from: https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/"},{"issue":"3","key":"1726_CR87","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/14740338.2025.2499670","volume":"25","author":"KL McCall","year":"2026","unstructured":"McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Exp Opin Drug Saf. 2026;25(3):581\u20138.","journal-title":"Exp Opin Drug Saf"},{"key":"1726_CR88","doi-asserted-by":"crossref","unstructured":"DiStefano MJ, Tilley A, Paratane D, Gyimah Gyamfi H, Moore GD, Nair KV, editors. Postshortage compounded GLP-1 RA market in 2 states with potentially high demand. JAMA Health Forum. American Medical Association; 2026.","DOI":"10.1001\/jamahealthforum.2026.2207"},{"issue":"8","key":"1726_CR89","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamapsychiatry.2026.1716","volume":"83","author":"N Peiper","year":"2026","unstructured":"Peiper N, Zibbell J, LaJoie A, Wahlang B, Krishnasamy S, Levinson C. Use and Misuse of GLP-1 Receptor agonists among people with eating disorders. JAMA Psychiatry. 2026;83(8):880.","journal-title":"JAMA Psychiatry"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-026-01726-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:02:55Z","timestamp":1794895375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-026-01726-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,17]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s11920-026-01726-9","relation":{},"ISSN":["1535-1645"],"issn-type":[{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,17]]},"assertion":[{"value":"14 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CMB receives royalties from Pearson Education, Inc. The other authors have nothing to disclose. Dr. Bulik is also the Founding Director of the Karolinska Institutet Centre for Eating Disorders Innovation (cynthia.bulik@ki.se).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"78"}}